CASI Pharmaceuticals Management
Management criteria checks 2/4
CASI Pharmaceuticals' CEO is Wei-Wu He, appointed in Apr 2019, has a tenure of 4.17 years. total yearly compensation is $9.67M, comprised of 3.3% salary and 96.7% bonuses, including company stock and options. directly owns 4.84% of the company’s shares, worth €1.25M. The average tenure of the management team and the board of directors is 3.8 years and 7.9 years respectively.
Key information
Wei-Wu He
Chief executive officer
US$9.7m
Total compensation
| CEO salary percentage | 3.3% |
| CEO tenure | 4.2yrs |
| CEO ownership | 4.8% |
| Management average tenure | 3.8yrs |
| Board average tenure | 7.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$38m |
| Dec 31 2022 | n/a | n/a | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$32m |
| Mar 31 2022 | n/a | n/a | -US$31m |
| Dec 31 2021 | US$10m | US$322k | -US$37m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$52m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$819k | US$578k | -US$48m |
| Sep 30 2020 | n/a | n/a | -US$47m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$9m | US$424k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$43m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$32m |
| Dec 31 2018 | US$6m | n/a | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$13m |
| Dec 31 2017 | US$781k | n/a | -US$11m |
| Sep 30 2017 | n/a | n/a | -US$8m |
| Jun 30 2017 | n/a | n/a | -US$8m |
| Mar 31 2017 | n/a | n/a | -US$9m |
| Dec 31 2016 | US$2m | n/a | -US$9m |
Compensation vs Market: Wei-Wu's total compensation ($USD9.67M) is above average for companies of similar size in the German market ($USD417.54K).
Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.
CEO
Wei-Wu He (58 yo)
4.2yrs
Tenure
US$9,665,359
Compensation
Dr. Wei-Wu He, Ph.D. is Chairman Emeritus at Genetron Holdings Limited since June 30, 2021 and served as its Chairman since May 2015 until June 30, 2021. He serves as Chairman and Chief Executive Officer a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.2yrs | US$9.67m | 4.84% $ 1.3m | |
| President | 3.8yrs | US$2.56m | 0.015% $ 3.9k | |
| Executive VP & Chief Medical Officer | 6.2yrs | US$1.18m | no data | |
| VP & Global Controller | 1.4yrs | no data | no data | |
| Chief Operating Officer | 5.3yrs | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Chief Commercial Officer | 1.9yrs | no data | no data | |
| VP & Global Controller | no data | no data | no data |
3.8yrs
Average Tenure
54yo
Average Age
Experienced Management: YZ3's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 11.3yrs | US$9.67m | 4.84% $ 1.3m | |
| Member of Scientific Advisory Board | 16.9yrs | no data | no data | |
| Independent Director | 10.2yrs | US$150.50k | no data | |
| Independent Director | no data | no data | no data | |
| Member of Clinical Advisory Board | 7.9yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Clinical Advisory Board | 7.9yrs | no data | no data | |
| Independent Director | 7.4yrs | no data | no data |
7.9yrs
Average Tenure
56.5yo
Average Age
Experienced Board: YZ3's board of directors are considered experienced (7.9 years average tenure).